Ikena Oncology (IKNA) Stock Price, News & Analysis

Company Overview

Ikena Oncology, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision small-molecule therapies for cancer. Since its founding in 2016, the company has built a pipeline targeting key processes in tumor cell division and chromatin regulation, aiming to address unmet needs in solid tumors and hematologic malignancies.

The company’s lead clinical candidates include a selective polo-like kinase 1 (PLK1) inhibitor designed to disrupt mitotic progression in advanced solid tumors and an inhibitor of the KDM5 family of histone demethylases that modulates epigenetic drivers of cancer cell survival. Additional preclinical programs are exploring novel targets implicated in oncogenic signaling and tumor resistance mechanisms. Ikena retains global development and commercialization rights for its internal portfolio and leverages collaborations with leading academic research centers to advance its pipeline.

Ikena operates research and development facilities in Cambridge and conducts multi-site clinical studies across North America and Europe. The company’s projects are supported by strategic partnerships and investigator-initiated trials aimed at optimizing patient selection and combination strategies. Manufacturing and scale-up activities are managed through experienced contract development and manufacturing organizations (CDMOs) in accordance with regulatory standards.

The leadership team at Ikena Oncology brings decades of combined experience in oncology drug development, regulatory affairs, and commercialization, with former executives and scientific leaders from industry-leading organizations. This management group guides the company’s clinical advancement and strategic planning as Ikena progresses toward regulatory filings and potential first‐in‐class approvals.

Key Stats

• Today's Range: $1.31 to $1.38
• 50-Day Range: $1.08 to $1.47
• 52-Week Range: $0.97 to $1.94
• Volume: 204,947 shs
• Average Volume: 115,637 shs
• Market Capitalization: $64.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Moderate Buy

Ikena Oncology Stock Analysis - MarketRank™

Ikena Oncology scored higher than 60% of companies evaluated by MarketBeat, and ranked 605th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ikena Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Ikena Oncology has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ikena Oncology are expected to grow in the coming year, from ($0.91) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ikena Oncology is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ikena Oncology is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ikena Oncology has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.39% of the float of Ikena Oncology has been sold short.

Short Interest Ratio / Days to Cover

Ikena Oncology has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ikena Oncology has recently increased by 0.75%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ikena Oncology does not currently pay a dividend.

Dividend Growth

Ikena Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.39% of the float of Ikena Oncology has been sold short.

Short Interest Ratio / Days to Cover

Ikena Oncology has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ikena Oncology has recently increased by 0.75%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.67

News Sentiment

Ikena Oncology has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ikena Oncology this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ikena Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.94% of the stock of Ikena Oncology is held by insiders.

Percentage Held by Institutions

75.00% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IKNA Stock Analysis - Frequently Asked Questions

How have IKNA shares performed this year?

Ikena Oncology's stock was trading at $1.64 on January 1st, 2025. Since then, IKNA shares have decreased by 18.3% and is now trading at $1.34.

How were Ikena Oncology's earnings last quarter?

Ikena Oncology, Inc. (NASDAQ:IKNA) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03.

When did Ikena Oncology IPO?

Ikena Oncology (IKNA) raised $125 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair acted as the underwriters for the IPO.

How do I buy shares of Ikena Oncology?

Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ikena Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ikena Oncology investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IKNA
• CIK: 1835579
• Web: ikenaoncology.com
• Phone: 857-273-8343
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ikena Oncology: $3.00
• High Price Target: $4.00
• Low Price Target: $2.00
• Potential Upside/Downside: +123.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.59%
• Return on Assets: -27.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.31
• Quick Ratio: 13.31

Sales & Book Value

• Annual Sales: $9.16 million
• Price / Sales: 7.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.61 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 48,260,000
• Free Float: 45,391,000
• Market Cap: $64.67 million
• Optionable: Not Optionable
• Beta: 0.50